- News
CSRA‘s (NYSE: CSRA) DynPort Vaccine subsidiary has been awarded a spot on a potential 10-year, $159 million contract to handle various medical product development initiatives for the National Institute of Allergy and Infectious Diseases. DynPort will work to create manufacturing processes and analytical test methods, characterize and manufacture products and provide regulatory support for the […] More